UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 65, 2026

___________________________________________

ARCUTIS BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________________________


Delaware	001-39186	81-2974255
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3027 Townsgate Road, Suite 300

Westlake Village, CA 91361

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (805) 418-5006

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

ARQT

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207 ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition.~~Vote of Security Holders

On ~~May 6~~June 5, 2026, Arcutis Biotherapeutics, Inc. (the “Company”) orheld its 2026 Annual Meeting of Stockholders (the “~~Arcutis~~Annual Meeting”). ~~issued~~At athe ~~press~~Annual ~~release~~Meeting, ~~relating~~the toCompany’s ~~its~~stockholders ~~financial~~voted ~~results~~on ~~for~~three proposals, each of which is described in more detail in the ~~quarter~~Company’s ~~ended~~definitive ~~March~~proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 3121, 2026. ~~The~~Only ~~full~~stockholders ~~text~~of record as of the ~~press~~close ~~release~~of isbusiness ~~furnished~~on ~~herewith~~April 8, as2026, ~~Exhibit~~the 99record date for the Annual Meeting, were entitled to vote at the Annual Meeting.1 As of the record date, 125,073,249 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. All matters voted on at the Annual Meeting were approved. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

~~The~~Proposal ~~information in this Item 2~~1.02 ofThe ~~this~~election ~~Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes~~ of ~~Section 18~~three ofClass ~~the~~III ~~Securities~~directors ~~Exchange~~to ~~Act~~hold ofoffice ~~1934,~~until ~~as amended (~~the ~~“Exchange~~2029 ~~Act”),~~annual ormeeting ~~otherwise subject to the liabilities~~ of ~~that~~stockholders ~~Section,~~ or ~~incorporated~~until bytheir ~~reference~~respective insuccessors ~~any~~are ~~filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.~~elected:

Item 9.01 Financial Statements and Exhibits.


Nominee	Votes for	Votes withheld	Broker Non-Votes
Patrick J. Heron	62,830,439	30,446,098	14,868,017
Neha Krishnamohan	74,956,903	18,319,634	14,868,017
Todd Franklin Watanabe	75,771,853	17,504,684	14,868,017

~~(d) Exhibits~~Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026:

Exhibit No.	Description
Votes for	Votes against	Abstentions
99.1	Press Release May 6, 2026.
107,867,442	15,748	261,364
104	Cover Page Interactive Data File (formatted as Inline XBRL).

Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company’s named executive officers:


Votes for	Votes against	Abstentions	Broker Non-Votes
88,728,269	3,723,408	824,860	14,868,017

Item 8.01 Other Events

As part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualified members of the Company’s Board of Directors (the “Board”), which includes compensating eligible non-employee directors appropriately for their services, the Compensation Committee of the Board recommended to the Board, and the Board approved, revisions to the Arcutis Biotherapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program (the “A&R Program”), which provides annual cash and equity compensation on the terms and conditions contained therein. The A&R Program became effective as of the Annual Meeting.

The foregoing description of the A&R Program is only a summary and is qualified in its entirety by the full text of the A&R Program, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.						Description
10.1						Amended and Restated Non-Employee Director Compensation Program
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARCUTIS BIOTHERAPEUTICS, INC.
	May 6, 2026	By:	/s/ Latha Vairavan
Date:	June 09, 2026	By:	/s/ Latha Vairavan
			Latha Vairavan
			Latha VairavanChief Financial Officer
			Chief Financial Officer

Filing Compare · Arcutis Biotherapeutics, Inc.